Comparative Efficacy Of Cabozantinib And Ramucirumab After Sorafenib For Patients With Advanced Hepatocellular Carcinoma And Afp >= 400 Ng/Ml

Cabozantinib (CAB) and ramucirumab (RAM) are approved for the treatment of adults with hepatocellular carcinoma (HCC) following sorafenib (SOR); RAM is restricted for use in patients with a serum α-fetoprotein (AFP) ≥400 ng/ml. The matching-adjusted indirect comparison (MAIC) evaluated the efficacy and safety of both agents after SOR in HCC patients with AFP≥400 ng/ml.